Pluvicto Therapy Overview

Pluvicto is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and are considered appropriate to delay taxane-based chemotherapy or have received prior taxane-based chemotherapy. This treatment is available at the Cancer Center at South Carolina Oncology Associates.

Pluvicto is given as an intravenous (IV) infusion. A full course of therapy is six doses of Pluvicto given 6 weeks apart. Therapy plans may vary depending on how your body responds to the treatment.

Patients referred for therapy should have a recent PSMA PET-CT showing evidence of PSMA avid metastatic disease, appropriate blood counts, renal function, and liver function. Requests for therapy will be reviewed by SCOA physicians to determine treatment eligibility. Insurance eligibility will also be completed prior to scheduling.